Mark Baldry bought $19k of XFOR
Chief Commercial Officer at X4 Pharmaceuticals, Inc. 35,050 shares at an average of $0.55, traded May 17, 2024, filed Feb 14, 2025.
Score components
- +15RoleOfficer
- 0Trade size$19k at market
- +6Relative to holdingsHoldings up 37%
- 0Price contextNo price history yet
- 0ClusterNo other insider buying within 14 days
- 0Repeat buyingFirst buy in 90 days
- 0Track recordToo few past buys to judge (0 with prices)
What happened after comparable buys
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001628280-25-005698, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| May 17, 2024 | POpen-market purchase Common Stock | +21,646 | $0.68 | $15k | 115,769 | Feb 14, 2025 |
| Nov 15, 2024 | POpen-market purchase Common Stock | +13,404 | $0.34 | $4,598 | 129,173 | Feb 14, 2025 |
| Feb 12, 2025 | AGrant or award Common Stock | +600,000 | $0.00 | $0 | 729,173 | Feb 14, 2025 |
Related signals
Other insiders at X4 Pharmaceuticals, Inc and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 28Weak | XFORsell X4 Pharmaceuticals, Inc | David Kirske Chief Financial Officer | $34k 11,767 shares | -7% | |
| 47Moderate | XFORbuy X4 Pharmaceuticals, Inc | Adam R Craig Executive Chairman | $250k 86,206 shares | +30% | |
| 33Weak | XFORbuy X4 Pharmaceuticals, Inc | Mark Baldry Chief Commercial Officer | $2,561 1,032 shares | +4% | |
| 20Weak | X4 Pharmaceuticals, Inc | Christophe Arbet-Engels Chief Medical Officer | $5,284 11,624 shares | -45% | |
| 15Weak | X4 Pharmaceuticals, Inc | Mark Baldry Chief Commercial Officer | $13k 29,159 shares | -24% | |
| 15Weak | X4 Pharmaceuticals, Inc | Mary DiBiase Chief Operating Officer | $10k 22,258 shares | -4% | |
| 5Weak | X4 Pharmaceuticals, Inc | Paula Ragan President and CEO | $13k 31,897 shares | -3% | |
| 5Weak | X4 Pharmaceuticals, Inc | Paula Ragan President and CEO | $18k 31,897 shares | -3% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.